Pediatric onset multiple sclerosis in Kuwait

IF 1.8 4区 医学 Q3 CLINICAL NEUROLOGY Clinical Neurology and Neurosurgery Pub Date : 2024-11-16 DOI:10.1016/j.clineuro.2024.108643
Raed Alroughani , Malak AlMojel , Dalal Qasem , Jasem Al-Hashel , Samar Farouk Ahmed
{"title":"Pediatric onset multiple sclerosis in Kuwait","authors":"Raed Alroughani ,&nbsp;Malak AlMojel ,&nbsp;Dalal Qasem ,&nbsp;Jasem Al-Hashel ,&nbsp;Samar Farouk Ahmed","doi":"10.1016/j.clineuro.2024.108643","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Epidemiological data of pediatric-onset multiple sclerosis (POMS) in the Middle East is limited.</div></div><div><h3>Objective</h3><div>To determine the demographic and clinical characteristics of POMS in Kuwait.</div></div><div><h3>Methods</h3><div>A retrospective study was conducted to assess the clinical characteristics of multiple sclerosis (MS) patients who disease onset started at age &lt; 18 years and fulfilled the International Pediatric MS Study Group (IPMSSG) criteria for MS.</div></div><div><h3>Results</h3><div>Of 249 POMS who were assessed, 70.3 % were female. The mean age at onset was 15.06 <u>+</u>11.78 years. Brainstem / cerebellar manifestation (34.9 %) were the most frequent presentation at onset of disease, followed by spinal (29.3 %) and visual pathway (27.3 %) symptoms. At the last follow-up visits, most of the patients (83.5 %) remained in a relapsing-remitting phenotype. The annual relapse rate (ARR) was 0.18 throughout the first 2 years while on treatment. At the baseline visit, the 51.4 % of the cohort-initiated platform therapies. Breakthrough disease (36.1 %) and adverse events (9.6 %) were the most common indications to escalate or switch to other disease-modifying drugs (DMTs).</div></div><div><h3>Conclusion</h3><div>Most POMS patients continued to be in a relapsing phenotype in our longitudinal study. Disease breakthrough is common in POMS especially when using platform therapies.</div></div>","PeriodicalId":10385,"journal":{"name":"Clinical Neurology and Neurosurgery","volume":"248 ","pages":"Article 108643"},"PeriodicalIF":1.8000,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Neurology and Neurosurgery","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0303846724005304","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Epidemiological data of pediatric-onset multiple sclerosis (POMS) in the Middle East is limited.

Objective

To determine the demographic and clinical characteristics of POMS in Kuwait.

Methods

A retrospective study was conducted to assess the clinical characteristics of multiple sclerosis (MS) patients who disease onset started at age < 18 years and fulfilled the International Pediatric MS Study Group (IPMSSG) criteria for MS.

Results

Of 249 POMS who were assessed, 70.3 % were female. The mean age at onset was 15.06 +11.78 years. Brainstem / cerebellar manifestation (34.9 %) were the most frequent presentation at onset of disease, followed by spinal (29.3 %) and visual pathway (27.3 %) symptoms. At the last follow-up visits, most of the patients (83.5 %) remained in a relapsing-remitting phenotype. The annual relapse rate (ARR) was 0.18 throughout the first 2 years while on treatment. At the baseline visit, the 51.4 % of the cohort-initiated platform therapies. Breakthrough disease (36.1 %) and adverse events (9.6 %) were the most common indications to escalate or switch to other disease-modifying drugs (DMTs).

Conclusion

Most POMS patients continued to be in a relapsing phenotype in our longitudinal study. Disease breakthrough is common in POMS especially when using platform therapies.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
科威特小儿多发性硬化症。
背景:中东地区小儿多发性硬化症(POMS)的流行病学数据有限:中东地区小儿多发性硬化症(POMS)的流行病学数据有限:确定科威特多发性硬化症患者的人口统计学和临床特征:方法:开展一项回顾性研究,评估发病年龄小于18岁、符合国际儿科多发性硬化症研究小组(IPMSSG)多发性硬化症标准的多发性硬化症(MS)患者的临床特征:在接受评估的249名多发性硬化症患者中,70.3%为女性。平均发病年龄为15.06 +11.78岁。脑干/小脑表现(34.9%)是发病时最常见的症状,其次是脊柱(29.3%)和视觉通路(27.3%)症状。在最后一次随访中,大多数患者(83.5%)仍处于复发-缓解表型。在接受治疗的头两年中,年复发率(ARR)为 0.18。在基线访视时,51.4%的患者启动了平台疗法。突破性疾病(36.1%)和不良反应(9.6%)是升级或改用其他改变病情药物(DMTs)的最常见指征:结论:在我们的纵向研究中,大多数POMS患者仍处于复发表型。结论:在我们的纵向研究中,大多数POMS患者仍处于复发表型,疾病突破在POMS患者中很常见,尤其是在使用平台疗法时。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Clinical Neurology and Neurosurgery
Clinical Neurology and Neurosurgery 医学-临床神经学
CiteScore
3.70
自引率
5.30%
发文量
358
审稿时长
46 days
期刊介绍: Clinical Neurology and Neurosurgery is devoted to publishing papers and reports on the clinical aspects of neurology and neurosurgery. It is an international forum for papers of high scientific standard that are of interest to Neurologists and Neurosurgeons world-wide.
期刊最新文献
Intraoperative indocyanine green (ICG) videoangiography in spinal hemangioblastoma surgery - helpful tool or unnecessary? The association between surgical start time and spine surgery outcomes The impact of access site on procedure time and post-anesthesia care unit (PACU) time in patients undergoing outpatient diagnostic angiograms: A propensity-score matched analysis stratified by body mass index Enhancing the diagnostic value of T2-FLAIR mismatch sign in IDH-mutated gliomas: Insights and future directions Treatment of patients with aneurysmal subarachnoid hemorrhage and multiple aneurysms: Concurrent versus delayed treatment
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1